---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-000413"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2022-01-05T23:59:59+00:00"
generated_at: "2026-06-27T20:41:06.354421+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Galecto files updated corporate presentation for January 2022 investor meetings

## Summary
- Presentation titled 'First-in-class small-molecule anti-fibrotic and anti-cancer agents'.
- Filed under Regulation FD; presentation dated January 2022.
- No specific new financial or pipeline details disclosed in the filing.

## SEC filing metadata
- accession: 0001564590-22-000413
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2022-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000156459022000413/0001564590-22-000413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000156459022000413/glto-8k_20220105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-000413
- JSON: https://secwatch.observer/filing/0001564590-22-000413.json
- Plain text: https://secwatch.observer/filing/0001564590-22-000413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.